includes vascular remodelling, glomerular hypertrophy, cardiomyocyte hypertrophy and angiogenesis. 7, 8 Importantly, tissue-based RAAS is more difficult to block than renal RAAS and require higher doses of ACE-inhibitors. Certain types of ACE-inhibitors (such as ramipril) are more lipophilic and could potentially have better tissue penetrance than others, 9 although this property was not clinically evident in studies comparing different types of ACE-inhibitors. 10 Secondly, Ang II can be generated independently of ACE, for example, via the catalytic actions of serine proteases, such as chymase, in a variety of tissues, including cardiac, vascular and renal tissue 11 . The percentage of locally generated Ang II in cardiac tissues is about 70%, while that in kidney tissues is about 20%, rising to 40% in diabetics. 12 Reducing the production of circulatory Ang II would remove the negative feedback upon renin and result in higher levels of renin and angiotensin I. 13, 14 As renin levels rise, ACE-inhibition becomes less effective and higher doses of ACE-inhibitors become necessary. 15 Plasma Ang II ultimately returns to normal with chronic use of recommended doses of ACE inhibitors. 16 This 'ACE escape' phenomenon could explain the additional benefit seen when increasing the doses of ACE inhibitors in heart failure and renal failure patients despite no further reductions to blood pressure. 17, 18 The availability of the angiotensin receptor blockers (ARBs), has enabled us to block Ang II at the AT1 receptor, regardless of site of action. Indeed, if Ang II which is generated independently of ACE is pathophysiologically of relevance, ARBs would have the
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upper hand in blocking the actions of ACE-independent Ang II. The 'ACE escape' phenomenon described above also suggests that there would be potential benefits in adding an ARB to ACE-inhibitor. Thus, it came as no surprise that early surrogate data indicated that the combination of an ACE inhibitor with a direct angiotensin II receptor blocker (ARB) improved left ventricular function and reduced neurohormonal levels. 19 In patients with essential hypertension, combination ARB and ACE inhibitor therapy succeeded only in modest systolic and diastolic blood pressure reduction as compared to monotherapy. 20, 21 Even then, these trials have been criticised for using sub-optimal doses of ACE-inhibitors when employed as monotherapy. Nevertheless, the early data on combination ARB and ACE inhibitor therapy have been recently substantiated by two studies, the Valsartan in Heart Failure Trial (Val HeFT) and the Candersartan And Lisinopril Microalbuminuria (CALM) study.
In Val HeFT, presented by Dr Jay Cohn at the American Heart Association scientific sessions in New Orleans, in November 2000, 5010 patients (mean age 62 years) with symptomatic heart failure (NYHA II-IV, with 62% NYHA II and 36% NYHA III) and dilated left ventricles (left ventricular enddiastolic diameter Ͼ2.9 cm/m 2 ) with ejection fraction Ͻ40%, were randomly assigned to standard therapy or standard therapy plus valsartan (forcetitrated from 40 mg b.i.d. to 160 mg b.i.d.). The majority (57%) had coronary artery disease and at baseline, 85% were taking diuretics, 67% digoxin, 35% beta-blockers, and 93% ACE inhibitors. There was no significant difference or benefit in all-cause mortality with valsartan (19.7% vs placebo 19.4%; RR 1.02, 95% CI 0.90-1.15; P = 0.8). However, the combined end point of 'all-cause mortality and morbidity' was significantly reduced in the valsartan group (28.8% vs 32.1% in placebo; RR 0.87, 95% CI 0.79-0.96; P = 0.009, with a dramatic reduction in hospitalisation rate. Importantly, the survival curves began to separate very early and separation rose throughout the follow-up period. In the valsartan group, 13.9% of patients had a first hospitalisation for heart failure, compared with 18.5% in the placebo arm (RR 0.73, 95% CI 0.63-0.83; P = 0.00001). Both NYHA class, subjective dyspnoea on exertion and echocardiographic ejection fraction also improved in the valsartan group. Patients who were not receiving an ACE inhibitor at the time of enrolment (7% of the population) appeared to have a benefit from valsartan (n = 185) over placebo (n = 181), with a 44.5% risk reduction in the combined end point of all-cause mortality and morbidity. In patients taking an ACE inhibitor, a nonsignificant trend toward an overall beneficial effect was seen, but in the patients taking both an ACE inhibitor and a beta-blocker, there was a trend favouring placebo (with wide 95% confidence intervals). However, in the 65% of patients not taking a betablocker, a striking benefit of valsartan was seen.
The CALM study was a prospective, randomised, parallel group, double-blind study of 199 patients aged 30-75 years, to assess and compare the effects of the ARB, candesartan 16 mg or the ACE inhibitor, lisinopril 20 mg, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. 22 At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, P Ͻ 0.001) was significantly greater than that with candesartan (10.4 mm Hg, P Ͻ 0.001) or lisinopril (mean 10.7 mm Hg, P Ͻ 0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 95% CI 36% to 61%, P Ͻ 0.001) was greater than with candesartan (24%, P = 0.05) and lisinopril (39%, P Ͻ 0.001). Thus candesartan 16 mg once daily was as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment was well tolerated and more effective in reducing blood pressure and the urinary albumin:creatinine ratio.
Val-HeFT and CALM are only the latest of clinical studies to push the case for combination therapy for treatment; in the management of heart failure, combination therapy has variously seen improvements to NYHA functional class, left ventricular function, exercise tolerance and reductions in ventricular volumes and total peripheral resistance. 23, 24 However, we are left with more questions than answers. On the one hand, the data from Val HeFT suggest a reduction in hospitalisations with valsartan. Subgroup analysis, however, suggests a possible adverse effect if valsartan is used in combination with a betablocker and an ACE inhibitor, which does raise the question that perhaps when beta-blockers are used, further inhibition of the RAAS may not be necessary or beneficial. The key question which will need to be answered in a prospective trial is, 'which is better?': an ACE inhibitor plus beta-blocker or an ACE inhibitor plus an ARB: In Val-HeFT, adding an ARB to standard therapy resulted in a further 13% reduction in hospitalisation and all-cause mortality but only a third of these patients were on beta-blockers. By contrast, MERIT-HF and CIBIS-II have both reported a clear 39% beneficial reduction in mortality, when beta-blockers were added to standard therapy in heart failure patients; therefore, betablockers must be the second drug added to an ACE inhibitor while treating systolic heart failure. 2, 25, 26 Based on Val HeFT, an ARB could potentially be the second drug if beta-blockers are contraindicated or not tolerated.
The fact that valsartan was substantially beneficial in patients not taking an ACE inhibitor suggests that ARBs may be a good substitute for ACE inhibitors if the latter are not tolerated. However, to date, no trial has shown equivalence of ARBs and ACE inhibitors in the treatment of heart failure. Despite initial hopes from ELITE-I, the recently published ELITE II trial failed to show superiority of losartan over cap-topril in outcome but was not powered as a noninferiority trial.
19,27 ELITE-II has similar treatment arms to the ongoing OPTIMAAL trial comparing captopril and losartan in patients post-myocardial infarction with left ventricular dysfunction, and may again show non-superiority of losartan over captopril. One also remembers the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study, 19 where mortality was 6.1% for the group receiving candesartan alone, 8.7% for those receiving candesartan plus enalapril and 3.7% for those receiving enalapril alone (P = 0.15), with heart failure hospitalisations of 10.7% with candesartan alone, 7.2% with candesartan plus enalapril, and 3.7% with enalapril alone (P = 0.048). Importantly, the combined end point of mortality plus hospitalisation rates were 14.6% for candesartan alone, 15.1% for candesartan plus enalapril, and 6.4% for enalapril alone (P = 0.058).
Nevertheless, heart failure trials like RALES, MERIT-HF and CIBIS-II have shown that much can be gained from combining different strategies of blocking the RAAS. 2, 25, 26, 28 With CHARM, VALIANT and OPTIMAAL all in progress and waiting to report in a few years, this may indeed be the case. 29 In CHARM, the addition of candesartan to an ACE inhibitor will be tested in patients with heart failure, in addition to a subgroup with heart failure due to diastolic dysfunction. The role of combination ARB and ACE inhibitor therapy in heart failure ± left ventricular dysfunction early post-myocardial infarction, is being tested in the VALIANT study. Time, data and P values will tell.
What does this mean for the patient with heart failure? Not only do we treat the patient with diuretic, ACE inhibitor, spironolactone and a betablocker, if they are in atrial fibrillation we add digoxin, and consider nitrates and hydralazine. Many will also be taking aspirin, despite the lack of evidence-based medicine for benefit and some analyses even suggesting some harm from aspirin in view of an interaction with the ACE inhibitors and warfarin may be better. 30 With Val-HeFT, we should add an ARB, especially if the patient is not taking a beta-blocker, which leaves the patient with a considerable pharmacological attack on the neurohormonal axis in heart failure. In hypertension, we await more data with interest but CALM suggests that in diabetics at least, combination of ARBs and an ACE inhibitor can only be advantageous, especially in light of the new recommended targets of blood pressure reduction in diabetics and the additional benefits in reducing diabetic proteinuria. Hopefully, we may avoid acronymmania with statements such as 'what is the VALUE of OPTIMAAL blockade of the renin-angiotensin system, and should these ELITE patients remain CALM, feel VALIANT or be RESOLVeD to polypharmacy?'
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